HIV infection and lymphoma

Grogg, Karen L.; Miller, R F; Doğan, Ahmet

doi:10.1136/jcp.2007.051953

Cited by 251 publications

(222 citation statements)

References 88 publications

(74 reference statements)

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…Burkitt lymphoma cells also show immunologic similarity to germinal center cells of B cell follicles rather than activated B cells, [2][3][4] being positive for Bcl-6, CD10, Tcl1, and CD38, and negative for Mum-1, CD44, CD138, and Bcl-2. However, germinal center (GC) markers are not specific for Burkitt lymphoma, since a significant proportion of diffuse large cell B cell lymphomas (DLBCL) also have this GC signature.…”

Section: Immunohistochemistrymentioning

confidence: 99%

See 1 more Smart Citation

Burkitt Lymphoma in Adults

Perkins

Friedberg²

2008

Hematology

105

View full text Add to dashboard Cite

This review will begin with a detail of the revision of the WHO classification, and pathological definitions of Burkitt lymphoma. Over the past several years, molecular understanding of Burkitt lymphoma has improved significantly. Using gene expression profiling, a genomic “signature” of Burkitt lymphoma may be identified, that has fidelity beyond c-myc expression, and the presence of the classical t(8;14). Then, evaluation and therapy of the adult patient with Burkitt lymphoma will be reviewed. Relatively few data exist on optimal therapy of the adult patient with Burkitt lymphoma. Principles of therapy should include high doses of alkylating agents, frequent administration of chemotherapy, and attention to central nervous system (CNS) prophylaxis with high doses of systemic chemotherapy, intrathecal therapy, or both. The outcome of adult patients with Burkitt lymphoma, particularly those over 40 years of age, is inferior to the outcome of younger patients, but may be improving over the past few years. Results from an international collaborative effort, which are helpful in evaluating results of Burkitt lymphoma therapy in adults, will be presented. HIV-associated Burkitt lymphoma, and elderly patients with Burkitt lymphoma, comprise special clinical situations that will be also covered in this review.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%

“…While EBV likely plays a key role in B-cell stimulation during a pre-lymphoma stage, the role for EBV after lymphoma development is unclear, as is whether EBV positivity is clinically meaningful. HIV is associated with Burkitt lymphoma 3 …”

Section: Immunohistochemistrymentioning

confidence: 99%

Burkitt Lymphoma in Adults

Perkins

Friedberg²

2008

Hematology

105

View full text Add to dashboard Cite

show abstract

“…Burkitt's lymphoma accounts for 30-50% of lymphomas in children and remains a serious health problem in those areas where it is endemic: namely the malarial belts of equatorial Africa, north-eastern Brazil, and Papua New Guinea 7 . In addition, because of its growing association with HIV infection, Burkitt's lymphoma is becoming a more common malignancy in adults, making up the largest group of HIV-associated non-Hodgkin lymphomas (35-50% of these neoplasms) 14 . A variety of chemotherapeutic drugs are used in the treatment of BL tumours including DNA intercalating agents and topoisomerase inhibitors.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents

McNamara¹,

Cloonan²,

Knox³

et al. 2011

Bioorganic & Medicinal Chemistry

View full text Add to dashboard Cite

Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents, Bioorganic & Medicinal Chemistry (2010), doi: 10.1016/j.bmc.2010 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. derived cell lines, whilst having no effect on 'normal' peripheral blood mononuclear cells. Such effects appear to be independent of the serotonin transporter, a high affinity target for amphetamines and independent of protein tyrosine phosphatases and tubulin dynamics both of which have been previously associated with nitrostyrene-induced cell death. We demonstrate that a number of these compounds induce caspase activation, PARP cleavage, chromatin condensation and membrane blebbing in a Burkitt's lymphoma-derived cell line, consistent with these compounds inducing apoptosis in vitro. Although no specific target has yet been identified for the action of these compounds, the cell death elicited is potent, selective and worthy of further investigation.

show abstract

“…Compared to the general population, the higher incidence of developing Burkitt lymphoma in HIV-affected individuals is attributed to transforming properties of the virus, immunosuppression, cytokine dysregulation, and opportunistic infections with other lymphotropic viruses like human-herpes virus 8 and Epstein-barr virus [12]. In addition to these, HIV is considered a neurotropic virus and can cause intra-neural edema with fiber swelling leading to signal enhancement on MRI [13].…”

Section: Discussionmentioning

confidence: 99%

Multiple cranial nerve palsies in immunodeficiency subtype of Burkitt lymphoma

Ali

Kalla

2018

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Burkitt lymphoma is a late complication of HIV, and bilateral cranial nerve palsies are extremely rare in patients with AIDS. A twenty year old Caucasian male with known congenital HIV who had been non-adherent with anti-retroviral therapy presented with multiple cranial nerve palsies and was eventually diagnosed with Burkitt lymphoma. Before chemotherapy, he was started on radiation therapy to the brain, meninges, and base of skull with the intent of improving cranial nerve palsies and preventing further neurological sequelae since the cranial nerve palsies were dense and there was concern that intrathecal chemotherapy would have less penetration than radiation. He eventually died due to overall disease burden. We hereby present what we believe is the first reported case of Burkitt lymphoma presenting with bilateral facial, vestibulocochlear, left abducens, and mandibular nerve palsies. Recognition of different presentations of Burkitt lymphoma is extremely important as it would aid in early diagnosis and initiation of both chemotherapy and anti-retroviral therapy potentially leading to improved outcomes.

show abstract

HIV infection and lymphoma

Cited by 251 publications

References 88 publications

Burkitt Lymphoma in Adults

Burkitt Lymphoma in Adults

Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents

Multiple cranial nerve palsies in immunodeficiency subtype of Burkitt lymphoma

Contact Info

Product

Resources

About